Living with stage 3 liver cancer: a long-term observation study
Part of Cancer, Digestive system clinical trials.
This study looks at people with advanced liver cancer that cannot be treated with surgery. It aims to gather information about the disease and how it is managed, which could help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been diagnosed with liver cancer that cannot be removed by surgery.
- Your liver cancer must be at stage III using the CNLC system.
- Your liver function must be in a good enough state (Child-Pugh grade A or B).
- You must not have received any prior treatment for liver cancer that goes throughout the body (like pills or IV).
- If you have hepatitis B, your virus level must be controlled or you must start antiviral treatment before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
This trial tests a combination of three treatments—chemo given directly into the liver, an oral targeted therapy, and an immunotherapy—for people with liver cancer that could be removed by surgery but isn't the first choice right now. The goal is to see if this combination can shrink the tumor and improve outcomes before surgery.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.